Emerging drugs in neuropathic pain

Expert Opinion on Emerging Drugs

Volumn 12, Issue 1, 2007, Pages 113-126

  Gilron, Ian ^a   Coderre, Terence J ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Chronic pain; Neuralgia; Neuropathic pain; Neuropathy; Radiculopathy

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; AJULEMIC ACID; AMITRIPTYLINE; AMITRIPTYLINE PLUS KETAMINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; AV 411; BICIFADINE; BRIVARACETAM; CANNABINOID; CAPSAICIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; DESVENLAFAXINE; DEXTROMETHORPHAN PLUS QUINIDINE; EPICEPT; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; GSK 644784; HARKOSERIDE; IBUDILAST; KETAMINE; LAMOTRIGINE; LIDOCAINE; NGX 4010; OPIATE; PLACEBO; RADAFAXINE; REBOXETINE; RESINIFERATOXIN; THALIDOMIDE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HUMAN; LOW DRUG DOSE; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; PATIENT CARE; PATIENT EDUCATION; PHYSIOTHERAPY; POSTHERPETIC NEURALGIA; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOSINE; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; ANTICONVULSANTS; CANNABINOIDS; CATECHOLAMINES; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEURALGIA; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; TRPV CATION CHANNELS;

EID: 33947702144     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.1.113     Document Type: Review

References (117)

1. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. In: Task force on taxonomy of the IASP, 2nd edn. Merskey H, Bogduk N (Eds) IASP Press, Seattle, WA, USA (1994):209-214. • Description of pain terms relevant to neuropathic pain.
2. BACKONJA MM: Defining neuropathic pain. Anesth. Analg. (2003) 97:785-790.
3. DWORKIN RH, BACKONJA M, ROWBOTHAM MC et al.: Advances in neuropathic pain. Arch. Neurol. (2003) 60:1524-1534. •• Review artide authored by a large panel of neuropathic pain experts, which makes several contemporary neuropathic pain treatment recommendations.
4. BOULTON AJ, ARMSTRONG WD, SCARPELLO JH, WARD JD: The natural history of painful diabetic neuropathy - a 4-year study. Postgrad. Med. J. (1983) 59:556-559.
5. MAX MB, SCHAFER SC, CULNANE M, DUBNER R, GRACELY RH: Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin. Pharmacol. Ther. (1988) 43:363-371.
6. FIELDS HL, ROWBOTHAM M, BARON R: Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. (1998) 5:209-227.
7. JENSEN TS, GOTTRUP H, SINDRUP SH, BACH FW: The clinical picture of neuropathic pain. Eur. J. Pharmacol. (2001) 429:1-11.
8. HELIOVAARA M, IMPIVAARA O, SIEVERS K et al.: Lumbar disc syndrome in Finland. J. Epidemiol. Community Health (1987) 41:251-258.
9. SCHMADER KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain (2002) 18:350-354. •• Review of epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy.
10. DAVIS MP, WALSH D: Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp. Palliat. Care (2004) 21:137-142.
11. VERMA S, ESTANISLAO L, SIMPSON D: HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs (2005) 19:325-334.
12. ARCHIBALD CP, SUTHERLAND J, GEDULD J, SUTHERLAND D, YAN P: Combining data sources to monitor the HIV epidemic in Canada. J Acquir Immune Defic Syndr (2003) 32(Suppl. 1):S24-S32.
13. HU R, MUSTARD CA, BURNS C: Epidemiology of incident spinal fracture in a complete population. Spine (1996) 21:492-499.
14. WERHAGEN L, BUDH CN, HULTLING C, MOLANDER C: Neuropathic pain after traumatic spinal cord injury-relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord (2004) 42:665-673.
15. SANDRONI P, BENRUD-LARSON LM, MCCLELLAND RL, LOW PA: Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain (2003) 103:199-207.
16. TORRANCE N, SMITH BH, BENNETT MI, LEE AJ: The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain (2006) 7(4):281-289.
17. ATLAS SJ, DEYO RA, PATRICK DL, CONVERY K, KELLER RB, SINGER DE: The Quebec Task Force classification for spinal disorders and the severity, treatment, and outcomes of sciatica and lumbar spinal stenosis. Spine (1996) 21:2885-2892.
18. COPLAN PM, SCHMADER K, NIKAS A et al.: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 5:344-356.
19. ZELMAN DC, DUKES E, BRANDENBURG N, BOSTROM A, GORE M: Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain (2005) 115:29-36.
20. BERGER A, DUKES EM, OSTER G: Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain (2004) 5:143-149.
21. TURK DC: Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin. J. Pain (2002) 18:355-365.
22. GILRON I, WATSON CP, CAHILL CM, MOULIN DE: Neuropathic pain: a practical guide for the clinician. CMAJ (2006) 175(3):265-275. • Clinician-oriented review of neuropathic pain mechanisms and treatments.
23. DESHPANDE MA, HOLDEN RR, GILRON I: The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Anesth. Analg. (2006) 102(5):1473-1479.
24. FINNERUP NB, OTTO M, MCQUAY HJ, JENSEN TS, SINDRUP SH: Algorithm for neuropathic pain treatment: an evidence based proposal. Pain (2005) 118:289-305. •• Recent systematic review of neuropathic pain clinical trials.
25. WANG LX, WANG ZJ: Animal and cellular models of chronic pain. Adv. DrugDeliv. Rev. (2003) 55(8):949-965. •• Review of preclinical pain models.
26. CAMPBELL JN, MEYER RA: Mechanisms of neuropathic pain. Neuron (2006) 52(1):77-92.
27. HANSSON PT, DICKENSON AH: Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain (2005) 113:251-254.
28. PARSONS CG: NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. (2001) 429(1-3):71-78.
29. DICKENSON AH, MATTHEWS EA, SUZUKI R: Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur. J. Pain. (2002) 6(Suppl. A):51-60.
30. TSUDA M, INOUE K, SALTER MW: Neuropathic pain and spinal microglia: a big problem from molecules in 'small' glia. Trends Neurosci. (2005) 28(2):101-107.
31. FUNDYTUS ME: Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs (2001) 15:29-58.
32. CHIZH BA, HEADLEY PM: NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr. Pharm. Des. (2005) 11:2977-2994.
33. CODERRE TJ, KUMAR N, LEFEBVRE CD, YU JSC: A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine and riluzole in a model of neuropathic pain. J. Neurochem. (2006) (In Press).
34. ZHANG W, MURAKAWA Y, WOZNIAK KM, SLUSHER B, SIMA AA: The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J. Neurol. Sci. (2006) 247:217-223.
35. SUNG B, LIM G, MAO J: Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J. Neurosci. (2003) 23:2899-2910.
36. BINNS BC, HUANG Y, GOETTL VM, HACKSHAW KV, STEPHENS RL Jr: Glutamate uptake is attenuated in spinal deep dorsal and ventral horn in the rat spinal nerve ligation model. Brain Res. (2005) 1041:38-47.
37. FISHER K, LEFEBVRE CD, CODERRE TJ: The effects of intrathecal administration of selective metabotropic glutamate receptor compounds in a rat model of neuropathic pain. Pharmacol. Biochem. Behav. (2002) 73:411-418.
38. BROWN DG, KRUPP JJ: N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr. Top. Med. Chem. (2006) 6:749-770.
39. GOGAS KR: Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. (2006) 6:68-74.
40. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned CDNA. Nature (1990) 346:561-564.
41. MUNRO S, THOMAS KL, ABU-SHAARM: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
42. DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
43. MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
44. SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptot ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89-97.
45. AZAD SC, RAMMES G: Cannabinoids in anaesthesia and pain therapy. Curr. Opin. Anaesthesiol (2005) 18:424-427.
46. PACHER P, BATKAI S, KUNOS G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. (2006) 58:389-462.
47. LEVER IJ, RICE AS: Cannabinoids and pain. Handbook Exp. Pharmacol. (2007) 177:265-306.
48. SMART D, GUNTHORPE MJ, JERMAN JC et al.: The endogenous lipid anandamide is a full agonist at the human vanilioid receptor (hVR1). Br. J. Pharmacol. (2000) 129:227-230.
49. MAIONE S, BISOGNO T, DE NOVELLIS V et al.: Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilioid type-1 receptors. J. Pharmacol. Exp. Ther. (2006) 316:969-982.
50. WATKINS LR, MAIER SF: Glia: a novel dtug discovery target for clinical pain. Nat. Rev. Drug Discov. (2003) 2:973-985.
51. MYERS RR, CAMPANA WM, SHUBAYEV VI: The role of neuroinflammation in neuroparhic pain: mechanisms and therapeutic targets. Drug Discov. Today (2006) 11:8-20.
52. MA W, QUIRION R: Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain (2002) 99:175-184.
53. ERIKSSON NP, PERSSON JK, SVENSSON M, ARVIDSSON J, MOLANDER C, ALDSKOGIUS H: A quantitative analysis of the microglial cell reaction in central primary sensory projection territories following peripheral nerve injury in the adult rat. Exp. Brain Res. (1993) 96:19-27.
54. MILLIGAN ED, TWINING C, CHACUR M et al.: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. (2003) 23:1026-1040.
55. LEDEBOER A, SLOANE EM, MILLIGAN ED et al.: Minocycline attenuates mechanical allodynia and proinflammarory cytokine expression in rat models of pain facilitation. Pain (2005) 115:71-83.
56. HASHIZUME H, DELEO JA, COLBURN RW, WEINSTEIN JN: Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine (2000) 25:1206-1217.
57. VERGE GM, MILLIGAN ED, MAIER SF, WATKINS LR, NAEVE GS, FOSTER AC: Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. (2004) 20:1150-1160.
58. LINDIA JA, MCGOWAN E, JOCHNOWITZ N, ABBADIE C: Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J. Pain (2005) 6:434-438.
59. MILLIGAN ED, ZAPATA V, CHACUR M et al.: Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. (2004) 20:2294-2302.
60. INOUE K: ATP receptors of microglia involved in pain. Novartis Found Symp. (2006) 276:263-272.
61. KIM SY, BAE JC, KIM J Y et al.: Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport (2002) 13:2483-2486.
62. OBATA K, YAMANAKA H, DAI Y et al.: Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur. J. Neurosci. (2004) 20:2881-2895.
63. CIRUELA A, DIXON AK, BRAMWELL S, GONZALEZ MI, PINNOCK RD, LEE K: Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br. J. Pharmacol. (2003) 138:751-756.
64. OBATA K, YAMANAKA H, KOBAYASHI K et al.: Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J. Neurosci. (2004) 24:10211-10222.
65. APFEL SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. (2002) 50:393-413.
66. HALVORSON KG, KUBOTA K, SEVCIK MA et al.: A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. (2005) 65:9426-9435.
67. HA SO, KIM JK, HONG HS, KIM DS, CHO HJ: Expression of brain-derived neurotrophic factor in rat dorsal root ganglia, spinal cord and gracile nuclei in experimental models of neuropathic pain. Neuroscience (2001) 107:301-309.
68. MILETIC G, MILETIC V: Increases in the concentration of brain derived neurotrophic factor in the lumbar spinal dorsal horn are associated with pain behavior following chronic constriction injury in rats. Neurosci. Lett. (2002) 319:137-140.
69. FUKUOKA T, KONDO E, DAI Y, HASHIMOTO N, NOGUCHI K: Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J. Neurosci. (2001) 21:4891-4900.
70. WHITE DM: Neurotrophin-3 antisense oligonucleotide attenuates nerve injury-induced Aβ-fibre sprouting. Brain Res. (2000) 885:79-86.
71. DONG ZQ, WANG YQ, MA F, XIE H, WU GC: Down-regulation of GFRα-1 expression by antisense oligodeoxynucleotide aggravates thermal hyperalgesia in a rat model of neuropathic pain. Neuropharmacology (2006) 50:393-403.
72. NEGUS SS, VANDERAH TW, BRANDT MR, BILSKY EJ, BECERRA L, BORSOOK D: Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J. Pharmacol. Exp. Ther. (2006) 319:507-514.
73. MAO J, PRICE DD, HAYES RL, LU J, MAYER DJ: Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res. (1992) 598(1-2):271-278.
74. SANG CN, BOOHER S, GILRON I, PARADA S, MAX MB: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology (2002) 96(5):1053-1061.
75. BIAN D, NICHOLS ML, OSSIPOV MH, LAI J, PORRECA F: Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport (1995) 6(15):1981-1984.
76. EISENBERG E, MCNICOL ED, CARR DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA (2005) 293(24):3043-3052.
77. MELLICK LB, MELLICK GA: Successful treatment of reflex sympathetic dystrophy with gabapentin. Am. J. Emerg. Med. (1995) 13:96.
78. SEGAL AZ, RORDORF G: Gabapentin as a novel treatment for postherpetic neuralgia. Neurology (1996) 46:1175-1176.
79. ROSNER H, RUBIN L, KESTENBAUM A: Gabapentin adjunctive therapy in neuropathic pain states. Clin. J. Pain (1996) 12:56-58.
80. XIAO WH, BENNETT GJ: Gabapentin has an antinociceptive effect mediated via a spinal site action in a rat model of painful peripheral neuropathy. Analgesia (1996) 2:267-273.
81. HWANG JH, YAKSH TL: Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Regional Anesthesia (1997) 22:249-256.
82. BACKONJA M, BEYDOUN A, EDWARDS KR et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA (1998) 280:1831-1836. •• Pivotal clinical trial of gabapentin in painful diabetic neuropathy.
83. ROWBOTHAM M, HARDEN N, STACEY B, BERNSTEIN P, MAGNUS-MILLER L: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA (1998) 280:1837-1842. •• Pivotal dinical trial of gabapentin in postherpetic neuralgia.
84. GILRON I, FLATTERS SJ: Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag. (2006) 11(Suppl. A):16A-29A.
85. LYNCH ME, CLARK AJ, SAWYNOK J, SULLIVAN MJ: Topical amitriptyline 2% and ketamine 1% in neuropathic pain syndromes: a randomized double blind placebo controlled trial. Anesthesiology (2005) 103:140-146.
86. SIMPSON S, BROWN S, CHANG S, JERMANO J; C107 STUDY GROUP: Controlled study of high-concentration capsaicin patch for painful HIV-associated distal sensory polyneuropathy. Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (2006) Abstract 79.
87. DEECHER DC, BEYER CE, JOHNSTON G et al.: Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther. (2006) 318(2):657-665.
88. EISENBERG E, LURIE Y, BRAKER C, DAOUD D, ISHAY A: Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology (2001) 57(3):505-509.
89. SAFIRSTEIN B, TUCHMAN M, DOGRA S et al.: Efficacy of lamotrigine in painful diabetic neuropathy: results from two large double-blind trials. J. Pain (2005) 6(Suppl. 3):S34.
90. GRAINGER J, HAMMER A, BLUM D, SILVER M, QUESSY S: Double-blind, placebo-controlled trial of add-on lamotrigine in patients with neuropathic pain and inadequate relief with gabapentin, TCAs or non-narcotic analgesics. J. Pain (2006) 7(Suppl. 2):S34.
91. HARATI Y, GOOCH C, SWENSON M et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology (1998) 50(6):1842-1846.
92. SINDRUP SH, ANDERSEN G, MADSEN C, SMITH T, BROSEN K, JENSEN TS: Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain (1999) 83:85-90.
93. BOUREAU F, LEGALLICIER P, KABIR-AHMADI M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain (2003) 104(1-2):323-331.
94. COLLINS SD, CHESSELL IP: Emerging therapies for neuropathic pain. Expert Opin. Emerg. Drugs (2005) 10(1):95-108. •• Recent review of emerging neuropathic pain treatments.
95. MATA M, GLORIOSO JC, FINK DJ: Gene therapy: novel treatments for polyneuropathy and chronic pain. Curr. Neurol. Neurosci. Rep. (2004) 4(1):1-2.
96. OXMAN MN, LEVIN MJ, JOHNSON GR et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. (2005) 352(22):2271-2284.
97. DAVIES PS, GALER BS: Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs (2004) 64(9):937-947.
98. GILRON I, MAX MB: Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev. Neurother. (2005) 5(6):823-830. • Review of combination therapy for neuropathic pain.
99. GILRON I, BAILEY JM, TU D, HOLDEN RR, WEAVER DF, HOULDEN RL: Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. (2005) 352(13):1324-1334.
100. MAX MB: Is mechanism-based pain treatment attainable? Clinical trial issues. J. Pain (2000) 1(3 Suppl.):2-9.
101. MAX MB, LYNCH SA, MUIR J, SHOAF SE, SMOLLER B, DUBNER R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl J. Med. (1992) 326:1250-1256.
102. ROWBOTHAM MC, REISNER LA, DAVIES PS, FIELDS HL: Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial. J. Pain (2005) 6:741-746.
103. WATSON CP, VERNICH L, CHIPMAN M, REED K: Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology (1998) 51:1166-1171.
104. RAJA SN, HAYTHORNTHWAITE JA, PAPPAGALLO M et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology (2002) 59:1015-1021.
105. MORELLO CM, LECKBAND SG, STONER CP, MOORHOUSE DF, SAHAGIAN GA: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. (1999) 159:1931-1937.
106. SINDRUP SH, BACH FW, MADSEN C, GRAM LF, JENSEN TS: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology (2003) 60:1284-1289.
107. http://www.pharmaprojects.com/
108. http://www.iddb.com/
109. http://www.clinicaltrials.gov/
110. http://www.controlled-trials.com/
111. http://www.epicept.com/
112. http://www.neurogesx.com/NewsPR.html
113. http://bioventureview.com
114. http://www.wyeth.com/research_hcp/pipeline_hcp
115. http://www.schwarzpharma.com/sp/n2579/Press_Releases/
116. http://www.gsk.com/
117. http://www.theraquestinc.com/news/pressrelease/pr_05_2_14.htm